“…This difference may be explained partially by the fact that her sample of men was relatively small (n=34), her CES-D scores were considerably higher in both gender groups than ours, and she entered only two predictors into her regression models. Our group and many others have reported that higher depressive symptoms were associated with a lower QOL (Bower, 2008; Brown & Roose, 2011; Dodd et al, 2011; Dunn et al, 2011; Fann et al, 2008; Miaskowski et al, 2014; Osann et al, 2014; Pud, 2011; Pulgar, Alcala, & Reyes del Paso, 2013; Roland et al, 2013) and other adverse outcomes, including reduced adherence to treatment and other health behaviors (DiMatteo, Lepper, & Croghan, 2000) and increased perception of pain and other symptoms (Dunn et al, 2011; Fann et al, 2008; Gaston-Johanssen, Ohly, Fall-Dickson, Nanda, & Kennedy, 1999; Huang, Chen, Liang, & Miaskowski, 2014). Our findings reinforce the need for clinicians to assess for and treat depressive symptoms in cancer patients at the beginning RT.…”